Biotech: Page 21
-
Permission granted by Cresilon
ProfileThis plant-based gel stops bleeding in seconds — and might have potential in drug delivery
29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.
By Karissa Waddick • Nov. 9, 2022 -
Amornrat Phuchom via Getty Images
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
By Michael Gibney • Nov. 8, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Permission granted by Rami Elghandour
ProfileChasing that ‘Time magazine cover potential’
Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.
By Alexandra Pecci • Nov. 8, 2022 -
Stock via Getty Images
After numerous setbacks, here’s where the Huntington’s pipeline stands
A look at emerging treatments and where there’s hope for patients.
By Kelly Bilodeau • Nov. 7, 2022 -
Image Source Trading Ltd/Shutterstock.com
Sponsored by CorEvitasReal world data: Understanding the scope of EHR and claims data
Using RWE alongside clinical trial data has the potential to streamline time-to-insight while generating a fuller and more patient-centric view of a given therapy’s efficacy.
Nov. 7, 2022 -
Stock via Getty Images
Acumen cruises into the fast lane with novel Alzheimer’s treatment
The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.
By Meagan Parrish • Nov. 3, 2022 -
Stock via Getty Images
OpinionPharma execs on creating a better workplace culture
Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.
By Taren Grom • Oct. 28, 2022 -
iStock via Getty Images
Q&A // Biotech SpotlightThe first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology
Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.
By Karissa Waddick • Oct. 27, 2022 -
Permission granted by Biogen
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
By Michael Gibney • Oct. 27, 2022 -
Permission granted by Tasuku Kitada
ProfileA longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level
The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.
By Alexandra Pecci • Oct. 25, 2022 -
Stock via Getty Images
Beyond cancer: Scientists push CAR-T cell therapies into new frontiers
Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.
By Kelly Bilodeau • Oct. 24, 2022 -
Stock via Getty Images
OpinionWhat’s keeping pharma leaders up at night
C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.
By Taren Grom • Oct. 21, 2022 -
Stock illustration via Getty Images
ProfileHow a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development
Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.
By Alexandra Pecci • Oct. 20, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
Stock via Getty Images
A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers
Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.
By Kelly Bilodeau • Oct. 18, 2022 -
Alex Wong via Getty Images
Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps
Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.
By Karissa Waddick • Oct. 18, 2022 -
Stock via Getty Images
The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan
Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.
By Meagan Parrish • Oct. 17, 2022 -
iStock via Getty Images
Making MovesBIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech
What these life science organizations’ latest executive-level appointments mean for the industry.
By Karissa Waddick • Oct. 14, 2022 -
iStock via Getty Images
Q&A // First 90 DaysComing out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
iStock via Getty Images
Robotic pills could open a world of possibilities for the biologics market
As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions.
By Karissa Waddick • Oct. 13, 2022 -
Permission granted by Ameet Mallik
Q&AWhere the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology
The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.
By Meagan Parrish • Oct. 12, 2022 -
skynesher via Getty Images
Q&A // Biotech SpotlightCitius Pharmaceuticals sees golden opportunities in late-stage specialty assets
CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.
By Karissa Waddick • Oct. 11, 2022 -
Permission granted by Amit Etkin
ProfileHarnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds
After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.
By Alexandra Pecci • Oct. 11, 2022 -
iStock via Getty Images
The digital therapeutics revolution is happening and Big Pharma is buying in — with caution
Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.
By Michael Gibney • Oct. 10, 2022 -
Stan Eales via Getty Images
Q&ANew partnership may give MDMA an edge in the psychedelics space
While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses.
By Kelly Bilodeau • Oct. 10, 2022
Previous
